Renalytix Plc Regulatory News (RENX)

Renalytix plc

("Renalytix" or the "Company")

Total Voting Rights

LONDON and NEW YORK, 28 June 2024 - Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces that at today's date, the Company's total issued share capital is 154,368,191 Ordinary Shares of £0.0025 each in the capital of the Company ("Ordinary Shares"). Each Ordinary Share carries the right to one vote at a general meeting of the Company. The Company does not hold any Ordinary Shares in treasury.

The above figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

For further information, please contact:

Renalytix (NASDAQ: RNLX) (LSE: RENX) is an artificial intelligence enabled in-vitro diagnostics and laboratory services company that is the global founder and leader in the field of bioprognosis™ for kidney health. In late 2023, our kidneyintelX.dkd test was recognized as the first and only FDA-authorized prognostic test to enable early-stage CKD (stages 1-3b) risk assessment for progressive decline in kidney function in T2D patients. By understanding how disease will progress, patients and clinicians can take action earlier to improve outcomes and reduce overall health system costs. For more information, visit www.renalytix.com.